Investing in small-cap health care companies can be tricky, with stocks that can soar or crash based on the results of a single clinical trial. However, equities.com's Small-Cap Stars, our proprietary list of small-cap companies with characteristics we've found to be most predictive of future success, isolates those companies that are best positioned to succeed.
Here are today's top performing health care Small-Cap Stars:
Insys Therapeutics Inc (INSY)
Insys Therapeutics Inc gained 6.43% to $34.75. The gains came on a volume of 601,741 shares against an average daily volume of 580,786 shares. Insys Therapeutics Inc has had a trading range from $57.91 to $15.89 over the last year, its P/E ratio is 22.8, it has a 50-day SMA of $28.08, and a 200-day SMA of $32.96.
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. It develops and commercializes supportive care products that target the unmet needs of cancer patients, with an initial focus on cancer supportive care.
Ampio Pharmaceuticals Inc. (AMPE)
Ampio Pharmaceuticals Inc. gained 6.3% to $6.92. The gains came on a volume of 846,024 shares against an average daily volume of 547,067 shares. Ampio Pharmaceuticals Inc. has had a trading range from $10.86 to $5.07 over the last year, it has a 50-day SMA of $7.12, and a 200-day SMA of $7.34.
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company, engaged in developing innovative, proprietary pharmaceutical drugs and diagnostic products to identify, treat and prevent human diseases including metabolic disorders, cancer etc.
Tg Therapeutics Inc. (TGTX)
Tg Therapeutics Inc. gained 5.32% to $7.92. The gains came on a volume of 292,595 shares against an average daily volume of 400,151 shares. Tg Therapeutics Inc. has had a trading range from $11.56 to $2.97 over the last year, it has a 50-day SMA of $8.75, and a 200-day SMA of $6.09.
TG Therapeutics Inc is a biopharmaceutical company focused on the acquisition, development & commercialization of medically important pharmaceutical products for the treatment of cancer & other underserved therapeutic needs.
Biocryst Pharmaceuticals Inc. (BCRX)
Biocryst Pharmaceuticals Inc. gained 4.11% to $13.92. The gains came on a volume of 1,253,660 shares against an average daily volume of 1,185,947 shares. Biocryst Pharmaceuticals Inc. has had a trading range from $14.62 to $4.55 over the last year, it has a 50-day SMA of $12.16, and a 200-day SMA of $9.65.
Biocryst Pharmaceuticals Inc. is engaged in the design, optimization and development of novel drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include Peramivir, BCX4161, Forodesine and Ulodesine, among others.
Galectin Therapeutics Inc. (GALT)
Galectin Therapeutics Inc. gained 3.69% to $4.78. The gains came on a volume of 403,686 shares against an average daily volume of 1,012,360 shares. Galectin Therapeutics Inc. has had a trading range from $19.11 to $4.28 over the last year, it has a 50-day SMA of $11.58, and a 200-day SMA of $11.74.
Galectin Therapeutics, Inc. is a development-stage company engaged in drug research and development to create new therapies for fibrotic disease and cancer.
Equities.com's Health Care Small-Cap Stars - Helping You Build a Healthier Portfolio
No one can predict precisely which potential treatments will fly through their clinical trials and which will stumble along the way. At least, if someone can, they're undoubtedly spectacularly wealthy right now. But, while the science is clearly the most important factor for the success of a small-cap biotech company, it's not the only one.
Equities.com's Small-Cap Stars system uses a complicated statistical regression to determine which fundamental factors previous success stories had in common and then identifies those present health care small caps that share those traits. For health care companies, we found that a high enterprise value, a strong value line beta, and a high rate of reinvestment were among the most important qualities in predicting the potential success of a company.
All data provided by QuoteMedia and was accurate as of 4:30 pm ET.